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Aims To determine clinical correlates and optimal treatment strategy in patients with cardiogenic shock
(CS) on admission.
Methods and results In SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?
(SHOCK) trial and registry patients with left ventricular (LV) dysfunction (n ¼ 1053), CS on admission
occurred in 26% of directly admitted patients (n ¼ 166/627). Time from myocardial infarction to CS
was shorter, initial haemodynamic proﬁle poorer, and aggressive treatment less frequent in CS on admis-
sion than in delayed CS patients. CS on admission patients constituted a smaller relative proportion
(11%) of the transferred (n ¼ 48/426) when compared with the directly admitted cohort (P , 0.001).
In-hospital mortality was higher (75 vs. 56%; P, 0.001) with more rapid death (24-h mortality 40 vs.
17%; P, 0.001) in CS on admission than in delayed CS patients. Emergency revascularization reduced
in-hospital mortality in CS on admission (60 vs. 82%; P ¼ 0.001) and in delayed CS patients similarly
(46 vs. 62%; P, 0.001; interaction P ¼ 0.25). After adjustment for clinical differences, CS on admission
was an independent predictor of in-hospital mortality (P ¼ 0.008).
Conclusion CS on admission patients have a worse outcome but beneﬁt equally from emergency revas-
cularization as delayed CS patients, emphasizing the need for rapid and direct access of CS on admission







Cardiogenic shock (CS) complicates acute myocardial infarc-
tion (AMI) in up to 10% of cases and remains the most
common cause of in-hospital death from AMI because of
high mortality rates.1 In up to one-quarter of the cases, CS
is already present when the patient arrives at the admit-
ting hospital.2–8 Care for this precipitously ill subgroup of
patients presenting with CS on admission is challenging
because of their severe haemodynamic compromise from
the outset and the expected high complication rates.
In a population with CS due to left ventricular (LV) failure,
emergency revascularization supported by intra-aortic
balloon counterpulsation has been tested in a randomized
trial and showed considerable survival beneﬁt with an absol-
ute mortality reduction of 13% after 1 year when compared
with initial medical stabilization.9 However, it is unclear
whether angiography and subsequent revascularization in
the critically ill and rapidly deteriorating patients with CS
on admission is safe and effective, or futile.10 If a clear
beneﬁt from an aggressive approach can be shown in
patients with CS on admission, they should undergo emer-
gency revascularization and intra-aortic counterpulsation,
and, thus, should directly be admitted to pre-deﬁned
regional specialized shock centres capable of emergency
cardiac catheterization and percutaneous or surgical
revascularization.11
Thus, we examined the SHould we emergently revascu-
larize Occluded Coronaries for cardiogenic shocK? (SHOCK)
trial and registry9,12,13 to investigate the incidence, clinical
characteristics, optimal therapeutic management, and out-
come of CS on admission in patients with CS complicating
AMI.
Methods
SHOCK trial and registry
This is a pre-speciﬁed subgroup analysis of the SHOCK trial and reg-
istry. Details of the SHOCK trial design and eligibility criteria have
been published previously.12,14 In brief, the SHOCK trial is a multi-
centre international randomized trial comparing the treatment
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strategies of emergency revascularization and initial medical stabil-
ization in CS complicating AMI. The protocol was approved by the
local institutional review board at every site. Written informed
consent was obtained by either the patient or a surrogate.
Enrolled patients had CS onset within 36 h post-AMI and were ran-
domized within 12 h of CS onset to either emergency revasculariza-
tion or initial medical stabilization. Patients assigned to the
emergency revascularization group had angioplasty or coronary
artery bypass graft surgery as early as possible and within 6 h
after randomization. In the initial medical stabilization group, ﬁbri-
nolytic therapy was strongly recommended, and delayed revascular-
ization (54 h after randomization) was allowed, if clinically
indicated. Intra-aortic balloon counterpulsation was recommended
for all patients.
Patients who had suspected CS but did not meet all inclusion cri-
teria, were outside the speciﬁed time windows, were unable or
refused to give consent, or had an exclusion criterion were enrolled
in the SHOCK registry.13 In these patients, treatment was left at the
discretion of the treating physicians, and follow-up was limited to
the hospitalization period. One-year follow-up for trial patients
were analysed in this report but was not available for registry
patients.
Patients and deﬁnitions
To obtain a more homogeneous population, only patients with CS
due to predominant LV failure were included in this analysis, i.e.
patients with severe valvular disease such as acute severe mitral
regurgitation or aortic stenosis, mechanical complications such as
ventricular rupture or tamponade, isolated right ventricular infarc-
tion, known dilated cardiomyopathy, CS resulting from excess beta-
or calcium-channel blockade, or a complication of a cardiac cathe-
terization were excluded. Patients were analysed using their clinical
status at admission to the initial hospital, and by treatment
received.
Trial patients were analysed in combination with the registry
patients (total cohort), whereas a separate analysis was performed
restricted to the trial patients to assess the effect of emergency
revascularization based on randomized treatment assignment. The
total cohort consisted of 1491 patients, of whom 314 (21%) had CS
owing to factors other than predominant LV failure and 124 (8%)
had missing information about clinical status at admission, leaving
1053 (71%) patients for analysis (Figure 1). The SHOCK trial subset
consisted of 302 patients, of whom eight (3%) had CS owing to
factors other than predominant LV failure and 31 (10%) had
missing information about clinical status at admission, leaving 263
(87%) patients for analysis. For all patients, a revascularization
attempt 18 h after CS was deﬁned as emergency revasculariza-
tion, whereas a revascularization attempt .18 h after CS or not
at all was deﬁned as no/late revascularization according to the
SHOCK trial’s time eligibility criteria. Patients in whom CS onset
was earlier or equal to the time of initial hospital admission were
classiﬁed as having CS on admission. Survival for the total cohort
was deﬁned as time from original admission to discharge.
Statistical analysis
Categorical variables were compared using Fisher’s exact test.
Continuous variables were compared using Student’s t-test for
normally distributed variables and Wilcoxon rank-sum test for non-
normally distributed variables. Descriptive statistics were presented
as means+SD, as medians with inter-quartile ranges, or as percen-
tages. The interaction between emergency revascularization and
admission status were tested for categorical variables by logistic
regression modelling and for continuous variables by analysis of var-
iance (ANOVA) between groups. The covariate-adjusted association
between in-hospital mortality and CS on admission was assessed by
multivariate logistic regression, in a ﬁrst step, considering all clini-
cal variables signiﬁcant in univariate analysis at P, 0.20, e.g.
admission status (transfer vs. direct admission), anoxic brain
Figure 1 Flowchart of patient sample.
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damage, peripheral hypoperfusion, heart rate, systolic blood
pressure, and lowest systolic blood pressure, retaining all variables
with a signiﬁcance level of P, 0.05 in the multivariate model. In a
second step, the association between in-hospital mortality and CS
on admission was additionally adjusted using variables assessed by
right heart catheterization considering all variables signiﬁcant in
univariate analysis at P, 0.20, i.e. cardiac power index and
stroke work index. The Kaplan–Meier method and log-rank test
were used to estimate and compare survival curves. All P-values
are two-sided and considered statistically signiﬁcant if 0.05.
Results
Patient sample
The total cohort included 1053 patients, of whom 214 (20%)
had CS on admission and 839 (80%) developed CS during hos-
pitalization. Among 627 direct admit patients, 166 (26%) had
CS on admission compared with 48 (11%) of 426 patients
transferred from outlying hospitals (P, 0.001).
Baseline characteristics
Patients with CS on admission had a shorter period between
AMI and CS onset than patients with delayed CS, a higher
rate of CS onset ,6 h after AMI and a lower rate of transfer
admissions, but were otherwise similar regarding baseline
demographic variables. Peripheral hypoperfusion and
anoxic brain damage occurred more often in patients with
CS on admission than in delayed CS patients (Table 1).
Patients with CS on admission had a poorer initial haemo-
dynamic proﬁle than patients with delayed CS, with lower
systolic blood pressure and stroke work index but similar
cardiac index, pulmonary capillary wedge pressure (PCWP),
systemic vascular resistance, and LV ejection fraction (EF)
(Table 2).
Treatment
Patients with CS on admission less often received ﬁbrinolytic
therapy, intra-aortic balloon counterpulsation, pulmonary
artery catheterization, cardiac catheterization, revasculari-
zation, and coronary artery bypass surgery, but were
mechanically ventilated more often when compared with
patients who developed CS during hospitalization
(Table 3). These differences were driven by the registry
cohort, as trial patients per protocol received similar treat-
ment. The cardiac catheterization rate was lower in
patients with CS on admission than in patients with
delayed CS, largely because of fewer angiograms in the
no/late revascularization patients likely as a result of
excess early deaths.
Mortality and effect of emergency
revascularization on outcome
The in-hospital mortality rate in the total cohort was higher
in patients with CS on admission (160/214, 75%) than in
patients with delayed CS (470/839, 56%; P, 0.001;
Figure 2). After adjustment for clinical variables that dif-
fered between the CS on admission and delayed CS groups,
i.e. admission status, anoxic brain damage, peripheral hypo-
perfusion, and systolic blood pressure, CS on admission was
still independently associated with in-hospital mortality
(n ¼ 899, odds ratio 1.68, 95% conﬁdence interval
1.14–2.46; P ¼ 0.008). However, after adjustment for stroke
work index, CS on admission was no longer signiﬁcant in the






Age (years) 68.3+ 11.9 68.1+ 11.8 0.777
Sex (male, %) 143 (66.8) 534 (63.7) 0.424
White race (%) 163 (77.3) 690 (82.6) 0.074
Transfer admission (%) 48 (22.4) 378 (45.1) ,0.001
History of hypertension (%) 105 (52.5) 418 (51.4) 0.813
Diabetes (%) 69 (33.5) 267 (32.4) 0.803
Hypercholesterolaemia [n ¼ 552, (%)] 39 (38.6) 179 (39.7) 0.911
History of smoking [n ¼ 900, (%)] 80 (48.5) 385 (52.4) 0.389
Prior myocardial infarction (%) 88 (42.5) 313 (38.5) 0.301
Prior PCI (%) 11 (5.5) 60 (7.3) 0.440
Prior coronary artery bypass graft surgery (%) 15 (7.3) 83 (10.0) 0.287
Prior congestive heart failure (%) 39 (19.5) 127 (15.7) 0.201
Prior renal failure (%) 15 (7.4) 76 (9.5) 0.413
Median creatinine clearance (mL/min) (n ¼ 690) 49.5 (22.8,67.0) 51 (31.4,72.1) 0.307
Median time MI to CS (h) 1.5 (0.5,4.1) 8.1 (2.8,21.0) ,0.001
Time MI to CS ,6 h (%) 154 (79.0) 341 (41.8) ,0.001
Median highest total CPK (U/L) (n ¼ 991) 2342 (516,4660) 2281 (834,4623) 0.501
CPR (%) (n ¼ 211) 10 (29.4) 37 (20.9) 0.269
VT or VF (%) (n ¼ 212) 9 (26.5) 41 (23.0) 0.663
Anoxic brain damage (%) 14 (6.9) 13 (1.6) ,0.001
Peripheral hypoperfusion (%) (n ¼ 989) 197 (97.5) 734 (93.3) 0.019
Continuous data are presented as mean+SD; skewed continuous data are presented as median (ﬁrst, third quartile). Data
are presented as number of patients with percentages unless deﬁned otherwise. All variables without given sample size have
,5% missing data. MI, myocardial infarction; CPK, creatine phosphokinase; CPR, cardiopulmonary resuscitation prior to
enrolment; VT, ventricular tachycardia prior to enrolment; VF, ventricular ﬁbrillation prior to enrolment.
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subset of patients with data available (n ¼ 347, odds ratio
1.25, 95% conﬁdence interval 0.66–2.37; P ¼ 0.495). There
was no signiﬁcant interaction between emergency revascu-
larization and admission status for in-hospital mortality
(P ¼ 0.25 for interaction), indicating a similar treatment
effect in both groups. Patients undergoing emergency revas-
cularization had a lower mortality rate than those with no/
late revascularization in both the CS on admission (40/67,
Table 2 Baseline haemodynamic, echocardiographic, and angiographic variables
Shock on admission (n ¼ 214) Delayed shock (n ¼ 839) P
Heart rate (b.p.m.)a 93.8+ 27.1 97.0+ 24.7 0.104
SBP (mmHg)a 84.1+ 27.2 89.0+ 21.1 0.017
Lowest SBP (mmHg) (n ¼ 770) 64.2+ 19.0 68.7+ 14.8 0.008
DBP (mmHg)a (n ¼ 886) 51.6+ 20.7 53.6+ 16.3 0.241
PCWP (mmHg)a (n ¼ 703) 24.9+ 8.3 23.8+ 8.2 0.196
Cardiac index (L/min/m2)a (n ¼ 590) 1.86+ 0.70 1.96+ 0.73 0.206
Median CPI (W/m2)a (n ¼ 536) 0.25 (0.21,0.33) 0.28 (0.21,0.36) 0.178
SVRI (dynes sec/cm5/m2)a (n ¼ 360) 2503+ 1177 2464+ 1084 0.812
Stroke work index (gm/m2)a (n ¼ 360) 9.3 (6.9,11.9) 11.5 (7.9,16.3) 0.020
Ejection fraction (%)a,b (n ¼ 289) 34.3+ 14.4 31.4+ 13.0 0.212
Number of diseased vessels (n ¼ 651) 0.549
0/1 (%) 21 (21.0) 97 (17.6)
2 (%) 23 (23.05) 115 (20.9)
3(%) 56 (56.0) 339 (61.5)
Culprit vessel (n ¼ 540) 0.102
Left main (%) 8 (9.9) 28 (6.1)
Left anterior descending (%) 31 (38.3) 224 (48.8)
Left circumﬂex (%) 14 (17.3) 65 (14.2)
Right (%) 26 (32.1) 140 (30.5)
Saphenous vein graft (%) 2 (2.5) 2 (0.4)
Continuous data are presented as mean+SD; skewed continuous data are presented as median (ﬁrst, third quartile). Data
are presented as number of patients with percentages unless deﬁned otherwise. All variables without given sample size have
,5% missing data.
aObtained while on support measures.
bObtained by echocardiography and angiography. CPI, cardiac power index.
Table 3 Therapeutic management

















Ventilator (%) 177 (82.7) 59 (88.1) 117 (80.1) 639 (76.2) 216 (83.7) 396 (73.1) 0.044
Pulmonary artery
catheterization (%)
131 (61.2) 52 (77.6) 78 (53.4) 610 (72.7) 212 (82.2) 367 (67.7) 0.001
Vasopressor/inotropes (%)
(n ¼ 850)
158 (99.4) 54 (98.2) 104 (100) 679 (98.3) 223 (98.7) 425 (98.2) 0.481
IABC (%) 111 (51.9) 56 (83.6) 54 (37.0) 512 (61.0) 221 (85.7) 263 (48.5) 0.016
Fibrinolytic therapy (%) 63 (29.4) 22 (32.8) 41 (28.1) 357 (42.7) 103 (39.9) 242 (44.8) ,0.001
Coronary angiography (%) 108 (50.5) 66 (98.5)b 41 (28.1) 571 (68.1) 256 (99.2)b 277 (51.1) ,0.001
Revascularization (%) 84 (39.3) 67 (100)a 16 (11.0) 410 (48.9) 258 (100)† 113 (20.9) 0.014
Revascularization




67 (80.7) 67 (100) — 258 (69.5) 258 (100) —
No/late
revascularization (%)
16 (19.3) — 16 (100) 113 (30.5) — 113 (100)
PCI (%) 69 (32.2) 61 (91.0)c 7 (4.8)c 270 (32.2) 191 (74.0)c 46 (8.5)c 1.000
CABG (%) 18 (8.4) 9 (13.4%) 9 (6.2) 161 (19.2) 83 (32.2) 70 (12.9) ,0.001
Data are presented as number of patients with percentages. All variables without given sample size have ,5% missing data.
IABC, intra-aortic balloon counterpulsation; CABG, coronary artery bypass graft surgery.
aForty patients had insufﬁcient data to classify as emergency or no/late revascularization.
bThree patients had coronary angiography immediately before shock onset without being repeated after shock onset.
cInteraction of shock on admission vs. delayed shock and emergency revascularization vs. no/late revascularization, P, 0.001.
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60% vs. 119/146, 82%; P ¼ 0.001) and delayed CS groups
(118/258, 46% vs. 338/542, 62%; P, 0.001). In the overall
group, mortality at 24 h was higher in patients with CS on
admission than in delayed CS patients (86/213, 40% vs.
139/837, 17%; P , 0.001).
To determine the effect of emergency revascularization
on outcome in patients with CS already present on admission
to the outlying hospitals and subsequently transferred to a
centre capable of revascularization, the CS on admission
cohort was classiﬁed by directly admitted vs. transferred
patients. Emergency revascularization was associated with
lower in-hospital mortality in both directly-admitted (31/
53, 59% vs. 94/112, 84%; P, 0.001) and transferred (9/14,
64% vs. 25/34, 74%; P ¼ 0.73) patients with CS on admission
(P ¼ 0.26 for interaction); however, the latter difference
was not signiﬁcant, probably because of a small sample size.
SHOCK trial cohort
The trial analysis cohort included 263 patients, of whom 40
(15%) had CS on admission and 223 (85%) had CS developing
during hospitalization. Among 132 directly admitted trial
patients, 31 (23%) presented with CS on admission when
compared with nine (7%) of 131 patients transferred from
outlying hospitals (P , 0.001).
Baseline differences between patients with CS on admis-
sion and delayed CS in the trial were similar to those in the
total cohort (data not shown). Despite protocol-directed
care, trial patients with CS on admission had a higher
in-hospital mortality than those with delayed CS (26/40,
68% vs. 108/223, 49%; P ¼ 0.039). Mortality rates at 30 days
(26/40, 65% vs. 108/223, 48%; P ¼ 0.060) and 1 year (29/40,
73% vs. 127/222, 57%; P ¼ 0.081) tended to be higher in
patients with CS on admission when compared with patients
with delayed CS, respectively (Figure 3). There was no signiﬁ-
cant interaction between emergency revascularization and
admission status for mortality either at 30 days (P ¼ 0.87
for interaction) or 1 year (P ¼ 0.85 for interaction).
Discussion
Our study shows that shock is diagnosed at hospital arrival in
as much as 26% of CS patients directly admitted to centres
capable of cardiac catheterization and revascularization.
Patients with CS on admission develop shock more rapidly
following AMI, have higher rates of anoxic brain damage
and peripheral hypoperfusion, display a worse initial haemo-
dynamic proﬁle, undergo fewer invasive procedures, and
suffer higher mortality than in patients with delayed CS.
After adjustment for important clinical baseline differen-
ces, CS on admission is highly signiﬁcantly associated with
in-hospital mortality, although this association disappears
after inclusion of right heart catheterization data, speciﬁ-
cally stroke work index, into the model. Despite their preci-
pitous critical condition, patients with CS on admission
beneﬁt equally from emergency revascularization as in
patients with delayed CS. Together, these observations
emphasize the need for patients with CS on admission to
be recognized and admitted expeditiously to facilities
capable of emergency invasive assessment and deﬁnitive
revascularization.
Proportion of shock on admission
Concordant with our ﬁndings, CS on admission has been
observed in up to one-quarter of patients in large CS regis-
tries and trials.2–8 However, in our study, the proportion of
CS on admission was higher among directly admitted than
in transferred patients probably because of a selection
bias in the latter, i.e. patients with CS on admission to com-
munity hospitals likely died too soon to be transferred than
the patients who developed CS during their hospitalization.
Thus, the higher proportion of CS on admission in directly
admitted patients may better reﬂect the real-world situ-
ation. In contrast, the fact that many patients developed
Figure 2 Estimated 7-day survival by timing of shock and treatment
received for the total cohort (n ¼ 1009). Patients who received emergency
revascularization (solid lines) had fewer deaths than those who had no/late
revascularization (dashed lines), both among those with shock on admission
(heavy lines) and those who developed shock (light lines). CSA, cardiogenic
shock on admission; CSD, delayed cardiogenic shock.
Figure 3 One-year survival by timing of shock and treatment received for
the SHOCK trial cohort (n ¼ 263). As in the total cohort, patients who
received emergency revascularization beneﬁted, regardless of shock status
on admission. CSA, cardiogenic shock on admission; CSD, delayed cardiogenic
shock.
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CS directly after treatment initiation and that the median
time between AMI and CS in patients with delayed CS was
more than 8 h raises the concern that iatrogenic factors,
e.g. drugs such as morphine, beta-blockers, ACE-inhibitors,
nitrates, and diuretics alone or in combination, may have
contributed to the development of severe hypotension
and, subsequently, shock.15,16
Mortality and timing of death
Several large studies performed in both tertiary care centres
and community hospitals showed similar mortality rates for
patients with CS on admission and delayed CS,3,6,7 whereas
others reported lower mortality rates in CS on admission.5,17
This contrasts with our observation that patients with CS on
admission had higher in-hospital mortality rates than those
with delayed CS, but can be explained by possible discre-
pancies in design (prospective vs. retrospective data
collection), CS deﬁnition, inclusion and exclusion criteria
(mechanical complications of AMI), transfer rates, and
treatment between the different studies. However, in our
study, the mortality rate for patients with CS on admission
might even be underestimated because death occurred
much more rapidly in patients with CS on admission than
in delayed CS; the mortality rate in the ﬁrst 24 h among
patients with CS on admission was more than double the
rate of patients with delayed CS. Because of this rapid
deterioration, it can be hypothesized that some patients
with CS on admission presenting to hospitals without cathe-
terization capabilities die before reaching the specialized
centre. This is supported by the ﬁnding that the proportion
of CS on admission among patients transferred from outly-
ing hospitals was less than half among directly-admitted
patients, as discussed earlier.
Effect of emergency revascularization
The use of an invasive treatment strategy in the setting of
CS has been studied in both retrospective analyses5,18–24
and randomized controlled trials9,12,25 and showed a bene-
ﬁcial effect of emergency revascularization on outcome.
However, given their poor haemodynamic situation at hospi-
tal arrival and their rapid deterioration, patients with CS on
admission are not likely to undergo cardiac catheterization
and revascularization. This was conﬁrmed in our study by
the ﬁnding that patients with CS on admission received
fewer invasive procedures than in patients with CS develop-
ing during the hospitalization. However, the survival beneﬁt
from emergency revascularization was similar in both CS on
admission and delayed CS groups. Although patients with CS
on admission had a poorer initial haemodynamic proﬁle than
the patients with delayed CS, they were of similar age and
had similar cardiovascular risk factors, LVEF, and extent of
diseased vessels (among those who underwent angiography).
It can be hypothesized that mechanisms other than more
severe structural damage may play a role in the rapid
clinical deterioration of patients with CS on admission
following AMI, i.e. a more intense and rapid systemic
inﬂammatory response, leading to greater haemodynamic
derangement.26
Given the rapid clinical deterioration and the beneﬁcial
effect of emergency revascularization in CS on admission,
our ﬁndings imply that patients arriving at the hospital in
CS should receive reperfusion therapy, preferably
percutaneous coronary intervention (PCI), as soon as poss-
ible. In addition, transfer protocols of emergency medical
services should include the direct transport of patients
with AMI complicated by CS to facilities capable of cardiac
catheterization and revascularization as outlined in
current guidelines.11 In case of pre-hospital transport,
patients with CS on admission should be transported directly
to specialized centres, whereas in case of initial presen-
tation to primary care hospitals, transfer to centres
capable of revascularization should occur immediately.
Following the example of regional trauma centres,27 desig-
nated regional shock centres could prove invaluable in redu-
cing mortality from CS.
Limitations
This database study is subject to inherent limitations. The
mortality rate for patients with CS on admission might
be underestimated as discussed earlier. Furthermore, the
true proportion of patients with CS on admission can only
be estimated from the direct admissions to the specialized
centres capable of cardiac catheterization and revasculari-
zation. This rate may be different at primary care hospitals.
Although our results suggest a more profound myocardial
dysfunction in patients with CS on admission, we do not
have mitral regurgitation grades or ventricular size on
most patients to further assess the reason for the lower
stroke work index.
Conclusion
CS on admission is associated with rapid and profound
haemodynamic deterioration that is more severe than in
delayed CS. This might explain the particularly poor early
and late outcome in this precipitously ill subgroup.
However, despite the gravity of illness with CS on admission,
these patients beneﬁt substantially from emergency revas-
cularization. Thus, patients with CS on admission need
immediate access to invasive assessment and deﬁnitive
revascularization by PCI or coronary artery bypass graft
surgery. Emergency medical services should, by protocol,
rapidly identify and transport patients with CS on admission
to pre-speciﬁed regional shock centres capable of providing
this care.
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